Ginkgo Bioworks Holdings Inc (NYSE: DNA) kicked off on Friday, down -3.46% from the previous trading day, before settling in for the closing price of $7.81. Over the past 52 weeks, DNA has traded in a range of $5.26-$51.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 76.14% over the past five years. While this was happening, its average annual earnings per share was recorded 41.63%. With a float of $36.99 million, this company’s outstanding shares have now reached $42.70 million.
Let’s look at the performance matrix of the company that is accounted for 834 employees. In terms of profitability, gross margin is 67.97%, operating margin of -238.06%, and the pretax margin is -241.15%.
Ginkgo Bioworks Holdings Inc (DNA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ginkgo Bioworks Holdings Inc is 32.78%, while institutional ownership is 57.92%. The most recent insider transaction that took place on Mar 07 ’25, was worth 767. Before that another transaction happened on Mar 04 ’25, when Company’s insider sold 395 for $7.72, making the entire transaction worth $3,051. This insider now owns 8,012 shares in total.
Ginkgo Bioworks Holdings Inc (DNA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.28% during the next five years compared to -27.97% drop over the previous five years of trading.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Take a look at Ginkgo Bioworks Holdings Inc’s (DNA) current performance indicators. Last quarter, stock had a quick ratio of 5.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -10.62, a number that is poised to hit -1.79 in the next quarter and is forecasted to reach -4.46 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Ginkgo Bioworks Holdings Inc (NYSE: DNA) saw its 5-day average volume 1.68 million, a negative change from its year-to-date volume of 1.81 million. As of the previous 9 days, the stock’s Stochastic %D was 12.47%. Additionally, its Average True Range was 1.26.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 14.11%, which indicates a significant increase from 5.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.84% in the past 14 days, which was lower than the 111.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.17, while its 200-day Moving Average is $11.29. Nevertheless, the first resistance level for the watch stands at $7.85 in the near term. At $8.17, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.55. If the price goes on to break the first support level at $7.15, it is likely to go to the next support level at $6.77. Assuming the price breaks the second support level, the third support level stands at $6.45.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
The company with the Market Capitalisation of 437.57 million has total of 58,034K Shares Outstanding. Its annual sales at the moment are 227,040 K in contrast with the sum of -547,030 K annual income. Company’s last quarter sales were recorded 43,850 K and last quarter income was -107,530 K.
